Tag: AAD
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant … –...
Extensive updates from broad and innovative portfolio also to be presented
The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the...
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent®...
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularisDupixent significantly reduced itch at 12...